about
A Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKDPharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study.Deficiencies in the reporting of VD and t(1/2) in the FDA approved chemotherapy drug inserts.Population pharmacokinetics of telapristone (CDB-4124) and its active monodemethylated metabolite CDB-4453, with a mixture model for total clearance.Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and ChildrenSelected pharmacokinetic issues in patients with chronic kidney disease.Medications in the kidney.Recommendations for the proper use of nonprescription cough suppressants and expectorants in solid-organ transplant recipients.Modeling and predicting drug pharmacokinetics in patients with renal impairment.Current understanding of drug disposition in kidney disease.Evaluation of potential interactions between mycophenolic acid derivatives and proton pump inhibitors.Estimating renal function to reduce the risk of adverse drug reactions.Treating epilepsy in the setting of medical comorbidities.Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis.Use of renal risk drugs in patients with renal impairment.Adherence with renal dosing recommendations in outpatients undergoing haemodialysis.Renal Targeted Therapies of Antihypertensive and Cardiovascular Drugs for Patients With Stages 3 Through 5d Kidney Disease.Pharmacotherapeutic considerations for chronic pain in chronic kidney and end-stage renal diseaseImpact of a renal drug dosing service on dose adjustment in hospitalized patients with chronic kidney disease.Medication-prescribing patterns of primary care physicians in chronic kidney disease.Pharmacokinetics of Aliskiren in Patients with End-Stage Renal Disease Undergoing Haemodialysis
P2860
Q28087621-6A5BCC01-8C30-4BFB-946B-C1BCBCB13C39Q33710330-0AF1528E-2CE2-4C13-8038-7C6EF48CF797Q35020052-0A925480-AF08-44FE-9C4A-600426531593Q35566515-E82DC9BF-891F-40A9-8626-DBBCA9EFA56FQ36322918-0D9050FA-63A9-49E6-B109-5390E13FAB1EQ36684744-714BE7AF-9E53-4545-83B0-1D488162B7DEQ37198832-73B008C0-BE73-4CE9-8245-BDCAE397BBBEQ37864309-5AE8DF31-D509-4C2A-833F-54BB4A7FC73AQ37960638-40E7C705-CF74-42FC-83A1-3633DE6C4C5CQ37974644-FE263E56-821B-4044-AF92-7D575A5AEC3CQ38027466-1E528FD9-9E27-41F6-AA70-3C5131393511Q38085223-F6E2AEBF-0E07-403D-9A7E-DE45380A1B4DQ38214818-D388D854-7E0D-4506-B324-8662CA3D1AFCQ38222867-73BAB028-B736-4C5F-91C6-918EE36F296FQ38568296-F7CC5D46-82E1-4B3E-956C-DECDC74E5D62Q38672320-DF0E58E0-31B2-4ADF-BF6A-051959A0BDD5Q38739039-02F48C88-8D5F-4F19-9EE2-C324A707A3CCQ42353634-8A7D0097-FBDA-46B9-BF87-20DAB7B0515CQ43272333-09CC2EAC-C8C2-4F6C-8EAB-D0D9D89C1834Q44707707-D6BA7108-AF6F-4645-A32C-A431B2412C2DQ56987287-01C73A5E-E690-4E19-BE28-AE9E0A4F08F3
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Drug dosing in chronic kidney disease.
@ast
Drug dosing in chronic kidney disease.
@en
type
label
Drug dosing in chronic kidney disease.
@ast
Drug dosing in chronic kidney disease.
@en
prefLabel
Drug dosing in chronic kidney disease.
@ast
Drug dosing in chronic kidney disease.
@en
P1476
Drug dosing in chronic kidney disease.
@en
P2093
Steven Gabardi
Stuart Abramson
P304
P356
10.1016/J.MCNA.2004.11.007
P577
2005-05-01T00:00:00Z